ClinicalTrials.gg
CompletedNCT02485691CARDUpdated May 27, 2022Results posted

Cabazitaxel Versus the Switch to Alternative AR-targeted Agent (Enzalutamide or Abiraterone) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Patients Previously Treated With Docetaxel and Who Rapidly Failed a Prior AR-targeted Agent

A Phase 4 interventional study of cabazitaxel XRP6258 and enzalutamide in Prostate Cancer Metastatic, sponsored by Sanofi. Completed at 65 sites in 13 countries. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-05-27.

Sponsored by Sanofi · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
255
Allocation
Randomized
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 46 studies testing cabazitaxel in Prostatic Neoplasms — 6 open to participants now, 10 under way, none of them phase 3. cabazitaxel · Prostatic Neoplasms.

Enrollment
8th of 46
255 · median 60
Started
2015
with 3 others
Phase 4
2 of 46
none open now
Registered
22nd of 46
by date
Lead sponsor
10 of 46
Sanofi

Among the 46 studies testing cabazitaxel in Prostatic Neoplasms, this one is the 8th largest by enrollment, is one of 4 that started in 2015, is one of 2 in phase 4, and was the 22nd registered.

Prostatic Neoplasms

7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,579 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

6 of the 46 studies testing cabazitaxel in Prostatic Neoplasms are open now, in 2 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About cabazitaxel

cabazitaxel: first FDA approval 2010 (JEVTANA KIT), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,228 Prostatic Neoplasms studies recruiting now, 927 (75%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 46 studies testing cabazitaxel in Prostatic Neoplasms, or all of them as a file.
02

Study summary

Primary Objective:

To compare the radiographic progression-free survival (rPFS) (using Response Evaluation Criteria in Solid Tumors [RECIST] 1.1 for tumor lesions and Prostate Cancer Working Group 2 (PCWG2) criteria for bone scan lesions or death due to any cause) with chemotherapy (cabazitaxel plus prednisone, Arm A) versus Androgen Receptor (AR)-targeted therapy (enzalutamide or abiraterone acetate plus prednisone, Arm B) in mCRPC participants who have been treated with docetaxel and who had disease progression while receiving AR-targeted therapy within 12 months of AR treatment initiation (less than or equal to [\<=]12 months, either before or after docetaxel).

Secondary Objective:

  • To compare efficacy for:
  • Prostate-specific antigen (PSA) response rate and time to PSA progression (TTPP).
  • Progression-free survival (PFS).
  • Overall survival (OS).
  • Tumor response rate and duration of tumor response.
  • Pain response and time to pain progression.
  • Symptomatic skeletal event (SSE) rate and time to occurrence of any SSE.
  • Health status and Health-related Quality of Life (HRQOL).
  • To evaluate the correlation of a signature of resistance to AR-targeted agents with clinical outcome via the analysis of circulating tumor cell (CTC) phenotypes as well as expression and localization of proteins including AR isoforms in CTCs.
  • To evaluate safety in the 2 treatment arms.
Read the detailed description

The duration of the study per participant was approximately 2 years. Each participant was treated until radiographic disease progression, unacceptable toxicity, or participant's refusal of further study treatment, and each participant was followed after completion of study treatment until death, study cut-off date, or withdrawal of participant consent.

03

Conditions studied

  • Prostate Cancer Metastatic

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

confirmed prostate adenocarcinoma.

  • disease.
  • Effective castration with serum testosterone levels less than (\<)0.5 ng/mL. If the participant has been treated with Luteinizing hormone-releasing hormone agonist (LHRH) agonists or antagonist (i.e., without orchiectomy), then this therapy should be continued.
  • Progressive disease defined by at least one of the following:
  • Progression in ( 1.1 criteria).
  • Appearance of 2 or more new bone lesions (PCWG2).
  • Rising Prostate Specific Antigen (PSA) (PCWG2).
  • Having received prior docetaxel for at least 3 cycles (before or after an AR-targeted therapy). Docetaxel administration in combination with androgen deprivation therapy (ADT) in metastatic hormone-sensitive disease was considered a prior exposure. Docetaxel rechallenge was allowed.
  • Having progressive disease (PD) while receiving AR-targeted therapy with abiraterone acetate or enzalutamide within 12 months of AR treatment initiation (\<=12 months), even if treatment duration was longer than 12 months. Participants treated with Abiraterone Acetate + ADT in metastatic hormone-sensitive setting were eligible in the study if they have progressed within 12 months with the AR-targeted agent. Participants having PSA progression only (as per PCWG2) within 12 months were eligible.
  • A PSA value of at least 2 ng/mL was required at study entry.
  • Prior AR-targeted therapy (abiraterone acetate or enzalutamide) must be stopped at least 2 weeks before study treatment.
  • Signed .

Exclusion criteria

Exclusion criteria:

  • Prior chemotherapy other than docetaxel for prostate cancer, except estramustine and except /neoadjuvant treatment completed >3 years ago.
  • Less than 28 days elapsed from prior treatment with chemotherapy, immunotherapy, radiotherapy, or surgery to the time of randomization.
  • Adverse events (excluding alopecia and those listed in the specific exclusion criteria) from any prior anticancer therapy of Grade >1 (National Cancer Institute Common Terminology Criteria [] v4.0) at the time of randomization.
  • performance status (ECOG PS) >2 (ECOG 2 must be related to prostate cancer, not to other comorbidities).
  • Prior . Adequately treated basal cell or squamous cell skin or superficial (pTis, pTa, and pT1) bladder cancer were allowed, as well as any other cancer for which treatment has been completed >=5 years ago and from which the participant has been disease-free for >=5 years.
  • Participation in another clinical trial and any concurrent treatment with any drug within 30 days prior to randomization.
  • Acquired immunodeficiency syndrome (AIDS-related illnesses) or known (HIV) disease requiring antiretroviral treatment.
  • Participants with who do not agree, in conjunction with their partner, to use accepted and effective method of during the study treatment period and up to 6 months after the last administered dose. The definition of "effective method of contraception" described hereafter: oral contraceptives, combined hormonal intravaginal, transdermal, intra uterine device or condoms was based on respective study treatment labelling and country-specific regulatory requirements, and were documented in the Form.
  • Known allergies, or intolerance to prednisone or of abiraterone acetate, enzalutamide, docetaxel, or polysorbate 80.
  • Known history of mineralocorticoid excess or deficiency.
  • History of seizure, underlying brain injury with loss of consciousness, within the past 12 months, cerebral vascular accident, brain arteriovenous malformation, , or the use of concomitant medications that may lower the seizure threshold.
  • Unable to swallow a whole tablet or capsule.
  • Inadequate organ and bone marrow function as evidenced by:
  • \<10.0 g/dL;
  • \<1.5 * 10\^9/L;
  • count \<100 * 10\^9/L;
  • /serum glutamic oxaloacetic transaminase and/or alanine aminotransferase/serum glutamic pyruvic transaminase >1.5 * the (ULN);
  • Total >1.0 * ULN;
  • Potassium \<3.5 mmol/L;
  • Class C.
  • to the use of treatment.
  • Symptomatic peripheral neuropathy Grade >=2 (NCI CTCAE v4.0).
  • Uncontrolled severe illness or medical condition including uncontrolled diabetes mellitus, history of cardiovascular disease (uncontrolled hypertension, arterial thrombotic events in the past 6 months, congestive heart failure, severe or unstable angina pectoris, recent myocardial infarction within the last 6 months, or uncontrolled cardiac arrhythmia).
  • Concomitant vaccination with yellow fever vaccine.

The above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

Terms in these criteria, in plain language(26)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
255 participants (actual)

Study arms

  • Experimental
    Cabazitaxel

    Participants received Cabazitaxel 25 mg/m\^2 intravenous (IV) infusion for over 1 hour on Day 1 of each 3 week treatment cycle in combination with Prednisone 10 mg orally once daily and primary prophylactic granulocyte-colony stimulating factor (G-CSF) as per investigator decision, until radiographic disease progression, unacceptable toxicity, or participant's refusal of further study treatment (median duration = 22 weeks).

    Drug: cabazitaxel XRP6258 · Drug: prednisone

  • Experimental
    Abiraterone acetate or enzalutamide

    Participants received either abiraterone acetate 1000 mg orally once daily from Day 1 to Day 21 of each 3 week treatment cycle in combination with prednisone 5 mg orally twice daily; or enzalutamide 160 mg orally once daily continuously from Day 1 to Day 21 of each 3 week treatment cycle, until radiographic disease progression, unacceptable toxicity, or participant's refusal of further study treatment (median duration = 12.5 weeks).

    Drug: enzalutamide · Drug: abiraterone acetate · Drug: prednisone

Interventions

  • Pharmaceutical form: solution Route of administration: intravenous

    Also known as: Jevtana

  • Pharmaceutical form: capsule Route of administration: oral

    Also known as: Xtandi

  • Pharmaceutical form: tablet Route of administration: oral

    Also known as: Zytiga

  • Pharmaceutical form: tablet Route of administration: oral

06

What researchers measure

Primary outcomes

  1. Radiographic Progression-Free Survival (rPFS)

    Radiographic progression-free survival: time (in months) from randomization to occurrence of any one of following: radiological tumor progressions using response evaluation criteria in solid tumors (RECIST 1.1), progression of bone lesions using Prostate Cancer Working Group 2 (PCWG2) criteria or occurrence of death due to any cause. Progression as per RECIST 1.1: at least a 20 percent (%) increase in sum of diameters of target lesions, unequivocal progression of existing non-target lesions. Progression of bone lesions (PCWG2 criteria): first bone scan with \>= 2 new lesions compared to Baseline observed less than (\<) 12 weeks from randomization and confirmed by a second bone scan performed \>=6 weeks; first bone scan with \>=2 new lesions compared to Baseline observed \>=12 weeks from randomization. In accordance with protocol, data cut-off date for final analysis of this endpoint was the date when 196 rPFS events had occurred. Analysis done by Kaplan-Meier method.

    Time frame: From randomization until tumor progression or bone lesion progression, death due to any cause, or data cut-off date whichever comes first (maximum duration: up to 141 weeks)

Secondary outcomes

  1. Overall Survival (OS)

    Overall survival was defined as the time interval (in months) from the date of randomization to the date of death due to any cause. In the absence of confirmation of death, survival time was censored at the last date participant was known to be alive, or at the cut-off date whichever comes first. Analysis was performed by Kaplan-Meier method.

    Time frame: From randomization to death due to any cause, or data cut-off date whichever comes first (maximum duration: up to 141 weeks)

  2. Progression Free Survival (PFS)

    PFS:time duration (in months) from date of randomization to date of first occurrence of any of following events: radiological tumor progression (RECIST 1.1); progression of bone lesions (PCWG2); symptomatic progression (developing urinary or bowel symptoms; need to change anti-cancer therapy), pain progression or death due to any cause. Tumor Progression(RECIST 1.1): at least 20% increase in sum of diameters of target lesions, unequivocal progression of existing non-target lesions. Progression of bone lesion (PCWG2 criteria): first bone scan with \>=2 new lesions compared to Baseline and confirmed by second bone scan performed \>=6 weeks later; pain progression: increase by \>=30% from Baseline in pain intensity score (calculated using scale ranged from 0=no pain to 5=extreme pain) or increase in analgesic usage score \>=30% (calculated from analgesic use data, non-narcotic medications assigned value of 1 point and narcotic medications assigned 4 points). Analyzed by Kaplan-Meier method.

    Time frame: From randomization until tumor progression or bone lesion progression, pain progression, death due to any cause, or data cut-off date whichever comes first (maximum duration: up to 141 weeks)

  3. Percentage of Participants With Prostate Specific Antigen (PSA) Response

    PSA response was defined as \>= 50% decrease from baseline in serum PSA levels, confirmed by a second PSA value at least 3 weeks later.

    Time frame: Baseline up to PSA response, death due to any cause or data cut-off date whichever comes first (maximum duration: up to 141 weeks)

  4. Percentage of Participants With Overall Objective Tumor Response

    Overall objective tumor response was defined as having a partial response (PR) or complete response (CR) according to the RECIST version 1.1. CR was defined as disappearance of all target and non-target lesions and normalization of tumor marker level. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.

    Time frame: From randomization until disease progression, death due to any cause or data cut-off date whichever comes first (maximum duration: up to 141 weeks)

  5. Time to PSA Progression (TTPP)

    TTPP was defined as the time duration (in months) between the date of randomization and the date of first documented PSA progression. PSA progression (as per PCWG 2) was defined as: 1) If decline from Baseline value: an increase of \>=25% (at least 2 ng/mL) over the nadir value, confirmed by a second PSA value at least 3 weeks apart; 2) If no decline from Baseline value: an increase of \>=25% (at least 2 ng/mL) over the baseline value after 12 weeks of treatment, confirmed by a second PSA value at least 3 weeks apart. Analysis performed by Kaplan-Meier method.

    Time frame: From time from randomization until PSA progression, death due to any cause or data cut-off whichever comes first (maximum duration: up to 141 weeks)

  6. Duration of Tumor Response

    Duration of tumor response was defined as the time (in months) from date of first response (CR or PR) until date of first documentation of tumor progression or death, whichever occurs first. As per RECIST 1.1 CR was defined as disappearance of all target and non-target lesions and normalization of tumor marker level. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Progression was defined as at least a 20% increase in sum of diameters of target lesions, unequivocal progression of existing non-target lesions. Analysis was performed by Kaplan-Meier method.

    Time frame: From the date of the first response to the date of first documented tumor progression, or death due to any cause or data cut-off date whichever comes first (maximum duration: up to 141 weeks)

  7. Percentage of Participants Achieving Pain Response Assessed Using Brief Pain Inventory-Short Form (BPI-SF) Pain Intensity Score

    Pain response as per BPI-SF was defined as a decrease of at least 30% from Baseline in the average of BPI-SF pain intensity score observed at 2 consecutive evaluations \>=3 weeks apart without increase in analgesic usage score (calculated from analgesic use data, with non-narcotic medications assigned value of 1 point and narcotic medications assigned 4 points). The BPI-SF is a self-administered questionnaire developed to assess the severity of pain on a 0-10 categorical scale where 0=no pain, 10=pain as bad as you can imagine. Higher scores indicated worst outcomes. Percentage of Participants Achieving Pain Response assessed using BPI-SF Pain Intensity Score were reported.

    Time frame: Baseline until pain progression, first further anticancer therapy, or data cut-off whichever comes first (maximum duration: up to 141 weeks)

  8. Time to Pain Progression

    Time to pain progression was defined as the time duration (in months) between the date of randomization and the date of first documented pain progression. Pain progression, in participants with no pain or stable pain at Baseline was defined as increase of \>=30% from baseline in the BPI-SF pain intensity score observed at 2 consecutive evaluations \>=3 weeks apart without decrease in analgesic usage score or increase in analgesic usage score (calculated from analgesic use data, with non-narcotic medications assigned value of 1 point and narcotic medications assigned 4 points) \>=30%. The BPI-SF is a self-administered questionnaire developed to assess the severity of pain on a 0-10 categorical scale where 0=no pain, 10=pain as bad as you can imagine. Higher scores indicated worst outcomes. Analysis was performed by Kaplan-Meier method.

    Time frame: Baseline until pain progression or data cut-off whichever comes first (maximum duration: up to 141 weeks)

  9. Number of Symptomatic Skeletal Events (SSE)

    SSE was defined as occurrence of a new symptomatic pathological fracture, use of external beam radiation to relieve bone pain, occurrence of spinal cord compression or tumor- related orthopedic surgical intervention.

    Time frame: Baseline until occurrence of first SSE or data cut-off, whichever comes first (maximum duration: up to 141 weeks)

  10. Time to Symptomatic Skeletal Event

    Time to SSE was defined as the time duration (in months) between the date of randomization and the date of occurrence of the first SSE. Analysis was performed by Kaplan-Meier method.

    Time frame: From date of randomization until first SSE, or data cut-off whichever comes first (maximum duration: up to 141 weeks)

  11. Health-Related Quality of Life (HRQOL): Change From Baseline in Functional Assessment of Cancer Therapy-Prostate (FACT-P) Total Score at Cycle 2, 3, 4, 5, 6, 7, 8 and End of Treatment

    Health-related quality of life (HRQOL) evaluation was performed using the FACT-P questionnaire (Version 4). FACT-P was a 39-item participant rated questionnaire that measures the concerns of participants with prostate cancer. It consisted of 5 sub-scales assessing physical well-being (7 items), social/family well-being (7 items), emotional well-being (6 items), functional well-being (7 items), and prostate-specific concerns (12 items). FACT-P total score was the sum of all 5 subscale scores. It ranged from 0 to156 with higher score indicated better quality of life with fewer symptoms. Baseline corresponded to last evaluable assessment before treatment administration.

    Time frame: Baseline, Day 1 of each Cycle 2, Cycle 3, Cycle 4, Cycle 5, Cycle 6, Cycle 7, Cycle 8 and at End of Treatment (any time up to 141 weeks)

  12. Change From Baseline in European Quality of Life Working Group Health Status Measure 5 Dimensions, 5 Levels (EQ-5D-5L) Utility Single Index and Visual Analogue Scale (VAS) Scores at Cycle 2, 3, 4, 5, 6, 7, 8 and End of Treatment

    EQ-5D was a standardized HRQOL questionnaire consisting of EQ-5D descriptive system and Visual Analogue Scale (VAS). EQ-5D descriptive system comprised of 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression measured on 3 levels (no problem, some problems \& severe problems) within a particular EQ-5D dimension. 5 dimensional 3-level system was converted into single index utility score. Possible values for single index utility score ranged from -0.594 (severe problems in all dimensions) to 1.0 (no problem in all dimensions) on scale where 1 represented best possible health state. EQ-5D VAS was used to record a participant's rating for his/her current health-related quality of life state and captured on a vertical VAS scale ranging from 0-100, where 0=worst imaginable health state and 100=best imaginable health state, where higher states indicated better outcomes. Baseline corresponded to last evaluable assessment before treatment administration.

    Time frame: Baseline, Day 1 of each Cycle 2, Cycle 3, Cycle 4, Cycle 5, Cycle 6, Cycle 7, Cycle 8 and at End of Treatment (any time up to: 141 weeks)

  13. Radiographic Progression-Free Survival (rPFS) in Participants With Presence and Absence of Biomarker

    Circulating tumor cell (CTC) counts were considered as biomarker in a liquid biopsy. rPFS in participants with presence and absence of subtypes of CTC biomarker i.e. chromosomal instability (CIN) and neuroendocrine (NE) was reported in this outcome measure. rPFS was defined as: time (in months) from randomization to the first occurrence of any one of following: radiological tumor progressions (RECIST1.1), progression of bone lesions (PCWG2 criteria) or death due to any cause. Progression (RECIST1.1): at least a 20% increase in sum of diameters of target lesions, unequivocal progression of existing non-target lesions. Progression of bone lesions (PCWG2 criteria): first bone scan with \>= 2 new lesions compared to Baseline observed \<12 weeks from randomization and confirmed by a second bone scan performed \>=6 weeks later; first bone scan with \>=2 new lesions compared to Baseline observed \>=12 weeks from randomization and new lesions were verified on next bone scan \>= 6 weeks later.

    Time frame: From randomization until tumor progression or bone lesion progression, death due to any cause, or data cut-off date whichever comes first (maximum duration: up to 141 weeks)

07

Results

Posted Feb 14, 2022

Participant flow

The study was conducted at 66 active centers in 13 countries. A total of 255 participants were randomized between 09 November 2015 to 13 November 2018, out of which 250 participants received treatment with the study drug.

Participant flow — Overall Study
MilestoneCabazitaxelAbiraterone Acetate or Enzalutamide
Started129126
Treated126124
Completed00
Not completed129126
Withdrew: Adverse event2511
Withdrew: Poor compliance to protocol01
Withdrew: Disease progression5792
Withdrew: Investigator's decision235
Withdrew: Participant's request136
Withdrew: Other reason89
Withdrew: Randomized and not treated32

Outcome measures

PrimaryRadiographic Progression-Free Survival (rPFS)

Radiographic progression-free survival: time (in months) from randomization to occurrence of any one of following: radiological tumor progressions using response evaluation criteria in solid tumors (RECIST 1.1), progression of bone lesions using Prostate Cancer Working Group 2 (PCWG2) criteria or occurrence of death due to any cause. Progression as per RECIST 1.1: at least a 20 percent (%) increase in sum of diameters of target lesions, unequivocal progression of existing non-target lesions. Progression of bone lesions (PCWG2 criteria): first bone scan with \>= 2 new lesions compared to Baseline observed less than (\<) 12 weeks from randomization and confirmed by a second bone scan performed \>=6 weeks; first bone scan with \>=2 new lesions compared to Baseline observed \>=12 weeks from randomization. In accordance with protocol, data cut-off date for final analysis of this endpoint was the date when 196 rPFS events had occurred. Analysis done by Kaplan-Meier method.

Time frame:
From randomization until tumor progression or bone lesion progression, death due to any cause, or data cut-off date whichever comes first (maximum duration: up to 141 weeks)
Reported as:
Median · months
Radiographic Progression-Free Survival (rPFS)
monthsCabazitaxelAbiraterone Acetate or Enzalutamide
Radiographic Progression-Free Survival (rPFS)8.0 (5.7 to 9.2)3.7 (2.8 to 5.1)
Statistical analysis
  • Cabazitaxel vs Abiraterone Acetate or Enzalutamide · Log Rank · p = <0.0001 (P-value from 2-sided stratified log-rank test, stratified for ECOG performance status, time from AR- targeted agent initiation progression, timing of AR targeted agent as specified at the time of randomization. Significance threshold was at 0.05.) · Hazard ratio (hr): 0.54 · 95% CI 0.40 to 0.73Cabazitaxel vs Abiraterone Acetate or Enzalutamide
SecondaryOverall Survival (OS)

Overall survival was defined as the time interval (in months) from the date of randomization to the date of death due to any cause. In the absence of confirmation of death, survival time was censored at the last date participant was known to be alive, or at the cut-off date whichever comes first. Analysis was performed by Kaplan-Meier method.

Time frame:
From randomization to death due to any cause, or data cut-off date whichever comes first (maximum duration: up to 141 weeks)
Reported as:
Median · months
Overall Survival (OS)
monthsCabazitaxelAbiraterone Acetate or Enzalutamide
Overall Survival (OS)13.6 (11.5 to 17.5)11.0 (9.2 to 12.9)
Statistical analysis
  • Cabazitaxel vs Abiraterone Acetate or Enzalutamide · Log Rank · p = 0.0078 (P-value from two-sided stratified log-rank test, stratified for ECOG performance status, time from AR-targeted agent initiation to progression, timing of AR-targeted agent as specified at the time of randomization. Significance threshold = 0.05.) · Hazard ratio (hr): 0.64 · 95% CI 0.46 to 0.89Cabazitaxel vs Abiraterone Acetate or Enzalutamide
SecondaryProgression Free Survival (PFS)

PFS:time duration (in months) from date of randomization to date of first occurrence of any of following events: radiological tumor progression (RECIST 1.1); progression of bone lesions (PCWG2); symptomatic progression (developing urinary or bowel symptoms; need to change anti-cancer therapy), pain progression or death due to any cause. Tumor Progression(RECIST 1.1): at least 20% increase in sum of diameters of target lesions, unequivocal progression of existing non-target lesions. Progression of bone lesion (PCWG2 criteria): first bone scan with \>=2 new lesions compared to Baseline and confirmed by second bone scan performed \>=6 weeks later; pain progression: increase by \>=30% from Baseline in pain intensity score (calculated using scale ranged from 0=no pain to 5=extreme pain) or increase in analgesic usage score \>=30% (calculated from analgesic use data, non-narcotic medications assigned value of 1 point and narcotic medications assigned 4 points). Analyzed by Kaplan-Meier method.

Time frame:
From randomization until tumor progression or bone lesion progression, pain progression, death due to any cause, or data cut-off date whichever comes first (maximum duration: up to 141 weeks)
Reported as:
Median · months
Progression Free Survival (PFS)
monthsCabazitaxelAbiraterone Acetate or Enzalutamide
Progression Free Survival (PFS)4.4 (3.6 to 5.4)2.7 (2.3 to 2.8)
Statistical analysis
  • Cabazitaxel vs Abiraterone Acetate or Enzalutamide · Log Rank · p = <0.0001 (P-value from two-sided stratified log-rank test, stratified for ECOG performance status, time from AR-targeted agent initiation to progression, timing of AR-targeted agent as specified at the time of randomization. Significance threshold = 0.05.) · Hazard ratio (hr): 0.52 · 95% CI 0.40 to 0.68Cabazitaxel vs Abiraterone Acetate or Enzalutamide
SecondaryPercentage of Participants With Prostate Specific Antigen (PSA) Response

PSA response was defined as \>= 50% decrease from baseline in serum PSA levels, confirmed by a second PSA value at least 3 weeks later.

Time frame:
Baseline up to PSA response, death due to any cause or data cut-off date whichever comes first (maximum duration: up to 141 weeks)
Reported as:
Number · percentage of participants
Percentage of Participants With Prostate Specific Antigen (PSA) Response
percentage of participantsCabazitaxelAbiraterone Acetate or Enzalutamide
Percentage of Participants With Prostate Specific Antigen (PSA) Response36.3 (27.4 to 45.1)14.3 (7.6 to 21.0)
Statistical analysis
  • Cabazitaxel vs Abiraterone Acetate or Enzalutamide · Cochran-Mantel-Haenszel · p = 0.0003 (Cochran-Mantel-Haenszel test stratified by ECOG performance status, time from AR-targeted agent initiation to progression, timing of AR-targeted agent as specified at the time of randomization. Significance threshold = 0.05.)
SecondaryPercentage of Participants With Overall Objective Tumor Response

Overall objective tumor response was defined as having a partial response (PR) or complete response (CR) according to the RECIST version 1.1. CR was defined as disappearance of all target and non-target lesions and normalization of tumor marker level. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.

Time frame:
From randomization until disease progression, death due to any cause or data cut-off date whichever comes first (maximum duration: up to 141 weeks)
Reported as:
Number · percentage of participants
Percentage of Participants With Overall Objective Tumor Response
percentage of participantsCabazitaxelAbiraterone Acetate or Enzalutamide
Percentage of Participants With Overall Objective Tumor Response36.5 (24.6 to 48.4)11.5 (2.9 to 20.2)
Statistical analysis
  • Cabazitaxel vs Abiraterone Acetate or Enzalutamide · Cochran-Mantel-Haenszel · p = 0.0004 (Cochran-Mantel-Haenszel test stratified by ECOG performance status, time from AR-targeted agent initiation to progression, timing of AR-targeted agent as specified at the time of randomization. Significance threshold = 0.05.)
SecondaryTime to PSA Progression (TTPP)

TTPP was defined as the time duration (in months) between the date of randomization and the date of first documented PSA progression. PSA progression (as per PCWG 2) was defined as: 1) If decline from Baseline value: an increase of \>=25% (at least 2 ng/mL) over the nadir value, confirmed by a second PSA value at least 3 weeks apart; 2) If no decline from Baseline value: an increase of \>=25% (at least 2 ng/mL) over the baseline value after 12 weeks of treatment, confirmed by a second PSA value at least 3 weeks apart. Analysis performed by Kaplan-Meier method.

Time frame:
From time from randomization until PSA progression, death due to any cause or data cut-off whichever comes first (maximum duration: up to 141 weeks)
Reported as:
Median · months
Time to PSA Progression (TTPP)
monthsCabazitaxelAbiraterone Acetate or Enzalutamide
Time to PSA Progression (TTPP)6.3 (4.2 to 8.3)2.1 (1.7 to 2.3)
SecondaryDuration of Tumor Response

Duration of tumor response was defined as the time (in months) from date of first response (CR or PR) until date of first documentation of tumor progression or death, whichever occurs first. As per RECIST 1.1 CR was defined as disappearance of all target and non-target lesions and normalization of tumor marker level. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Progression was defined as at least a 20% increase in sum of diameters of target lesions, unequivocal progression of existing non-target lesions. Analysis was performed by Kaplan-Meier method.

Time frame:
From the date of the first response to the date of first documented tumor progression, or death due to any cause or data cut-off date whichever comes first (maximum duration: up to 141 weeks)
Reported as:
Median · months
Duration of Tumor Response
monthsCabazitaxelAbiraterone Acetate or Enzalutamide
Duration of Tumor Response6.5 (5.6 to 11.4)8.0 (1.1 to NA)
SecondaryPercentage of Participants Achieving Pain Response Assessed Using Brief Pain Inventory-Short Form (BPI-SF) Pain Intensity Score

Pain response as per BPI-SF was defined as a decrease of at least 30% from Baseline in the average of BPI-SF pain intensity score observed at 2 consecutive evaluations \>=3 weeks apart without increase in analgesic usage score (calculated from analgesic use data, with non-narcotic medications assigned value of 1 point and narcotic medications assigned 4 points). The BPI-SF is a self-administered questionnaire developed to assess the severity of pain on a 0-10 categorical scale where 0=no pain, 10=pain as bad as you can imagine. Higher scores indicated worst outcomes. Percentage of Participants Achieving Pain Response assessed using BPI-SF Pain Intensity Score were reported.

Time frame:
Baseline until pain progression, first further anticancer therapy, or data cut-off whichever comes first (maximum duration: up to 141 weeks)
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Pain Response Assessed Using Brief Pain Inventory-Short Form (BPI-SF) Pain Intensity Score
percentage of participantsCabazitaxelAbiraterone Acetate or Enzalutamide
Percentage of Participants Achieving Pain Response Assessed Using Brief Pain Inventory-Short Form (BPI-SF) Pain Intensity Score45.9 (36.7 to 55.2)19.3 (11.9 to 26.7)
SecondaryTime to Pain Progression

Time to pain progression was defined as the time duration (in months) between the date of randomization and the date of first documented pain progression. Pain progression, in participants with no pain or stable pain at Baseline was defined as increase of \>=30% from baseline in the BPI-SF pain intensity score observed at 2 consecutive evaluations \>=3 weeks apart without decrease in analgesic usage score or increase in analgesic usage score (calculated from analgesic use data, with non-narcotic medications assigned value of 1 point and narcotic medications assigned 4 points) \>=30%. The BPI-SF is a self-administered questionnaire developed to assess the severity of pain on a 0-10 categorical scale where 0=no pain, 10=pain as bad as you can imagine. Higher scores indicated worst outcomes. Analysis was performed by Kaplan-Meier method.

Time frame:
Baseline until pain progression or data cut-off whichever comes first (maximum duration: up to 141 weeks)
Reported as:
Median · months
Time to Pain Progression
monthsCabazitaxelAbiraterone Acetate or Enzalutamide
Time to Pain ProgressionNA (NA to NA)8.5 (4.9 to NA)
SecondaryNumber of Symptomatic Skeletal Events (SSE)

SSE was defined as occurrence of a new symptomatic pathological fracture, use of external beam radiation to relieve bone pain, occurrence of spinal cord compression or tumor- related orthopedic surgical intervention.

Time frame:
Baseline until occurrence of first SSE or data cut-off, whichever comes first (maximum duration: up to 141 weeks)
Reported as:
Number · events
Number of Symptomatic Skeletal Events (SSE)
eventsCabazitaxelAbiraterone Acetate or Enzalutamide
Number of Symptomatic Skeletal Events (SSE)2435
SecondaryTime to Symptomatic Skeletal Event

Time to SSE was defined as the time duration (in months) between the date of randomization and the date of occurrence of the first SSE. Analysis was performed by Kaplan-Meier method.

Time frame:
From date of randomization until first SSE, or data cut-off whichever comes first (maximum duration: up to 141 weeks)
Reported as:
Median · months
Time to Symptomatic Skeletal Event
monthsCabazitaxelAbiraterone Acetate or Enzalutamide
Time to Symptomatic Skeletal EventNA (20.0 to NA)16.7 (10.8 to NA)
SecondaryHealth-Related Quality of Life (HRQOL): Change From Baseline in Functional Assessment of Cancer Therapy-Prostate (FACT-P) Total Score at Cycle 2, 3, 4, 5, 6, 7, 8 and End of Treatment

Health-related quality of life (HRQOL) evaluation was performed using the FACT-P questionnaire (Version 4). FACT-P was a 39-item participant rated questionnaire that measures the concerns of participants with prostate cancer. It consisted of 5 sub-scales assessing physical well-being (7 items), social/family well-being (7 items), emotional well-being (6 items), functional well-being (7 items), and prostate-specific concerns (12 items). FACT-P total score was the sum of all 5 subscale scores. It ranged from 0 to156 with higher score indicated better quality of life with fewer symptoms. Baseline corresponded to last evaluable assessment before treatment administration.

Time frame:
Baseline, Day 1 of each Cycle 2, Cycle 3, Cycle 4, Cycle 5, Cycle 6, Cycle 7, Cycle 8 and at End of Treatment (any time up to 141 weeks)
Reported as:
Mean · score on a scale
Health-Related Quality of Life (HRQOL): Change From Baseline in Functional Assessment of Cancer Therapy-Prostate (FACT-P) Total Score at Cycle 2, 3, 4, 5, 6, 7, 8 and End of Treatment
score on a scaleCabazitaxelAbiraterone Acetate or Enzalutamide
Cycle 22.6 ± 12.3-0.0 ± 12.4
Cycle 32.7 ± 16.1-1.0 ± 16.8
Cycle 42.8 ± 14.8-0.7 ± 16.8
Cycle 52.1 ± 17.9-1.0 ± 16.1
Cycle 6-3.7 ± 18.00.4 ± 18.6
Cycle 7-2.2 ± 19.32.7 ± 19.9
Cycle 8-4.8 ± 20.40.8 ± 23.0
End of treatment-6.3 ± 16.1-7.5 ± 15.7
SecondaryChange From Baseline in European Quality of Life Working Group Health Status Measure 5 Dimensions, 5 Levels (EQ-5D-5L) Utility Single Index and Visual Analogue Scale (VAS) Scores at Cycle 2, 3, 4, 5, 6, 7, 8 and End of Treatment

EQ-5D was a standardized HRQOL questionnaire consisting of EQ-5D descriptive system and Visual Analogue Scale (VAS). EQ-5D descriptive system comprised of 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression measured on 3 levels (no problem, some problems \& severe problems) within a particular EQ-5D dimension. 5 dimensional 3-level system was converted into single index utility score. Possible values for single index utility score ranged from -0.594 (severe problems in all dimensions) to 1.0 (no problem in all dimensions) on scale where 1 represented best possible health state. EQ-5D VAS was used to record a participant's rating for his/her current health-related quality of life state and captured on a vertical VAS scale ranging from 0-100, where 0=worst imaginable health state and 100=best imaginable health state, where higher states indicated better outcomes. Baseline corresponded to last evaluable assessment before treatment administration.

Time frame:
Baseline, Day 1 of each Cycle 2, Cycle 3, Cycle 4, Cycle 5, Cycle 6, Cycle 7, Cycle 8 and at End of Treatment (any time up to: 141 weeks)
Reported as:
Mean · score on a scale
Change From Baseline in European Quality of Life Working Group Health Status Measure 5 Dimensions, 5 Levels (EQ-5D-5L) Utility Single Index and Visual Analogue Scale (VAS) Scores at Cycle 2, 3, 4, 5, 6, 7, 8 and End of Treatment
score on a scaleCabazitaxelAbiraterone Acetate or Enzalutamide
Cycle 2: VAS3.6 ± 14.40.9 ± 14.6
Cycle 3: VAS4.5 ± 15.01.5 ± 13.4
Cycle 4: VAS4.6 ± 16.5-1.1 ± 18.2
Cycle 5: VAS0.6 ± 17.13.2 ± 17.0
Cycle 6: VAS-1.3 ± 22.8-1.5 ± 23.1
Cycle 7: VAS2.9 ± 18.1-0.2 ± 20.1
Cycle 8: VAS2.8 ± 18.01.2 ± 19.6
End of treatment: VAS-3.3 ± 19.3-5.9 ± 23.1
Cycle 2: Utility Index Score0.026 ± 0.179-0.010 ± 0.178
Cycle 3: Utility Index Score0.041 ± 0.183-0.011 ± 0.182
Cycle 4: Utility Index Score0.051 ± 0.176-0.002 ± 0.188
Cycle 5: Utility Index Score0.027 ± 0.209-0.035 ± 0.185
Cycle 6: Utility Index Score0.015 ± 0.191-0.000 ± 0.176
Cycle 7: Utility Index Score0.029 ± 0.1820.024 ± 0.153
Cycle 8: Utility Index Score0.008 ± 0.213-0.014 ± 0.138
End of treatment: Utility Index Score-0.048 ± 0.188-0.079 ± 0.200
SecondaryRadiographic Progression-Free Survival (rPFS) in Participants With Presence and Absence of Biomarker

Circulating tumor cell (CTC) counts were considered as biomarker in a liquid biopsy. rPFS in participants with presence and absence of subtypes of CTC biomarker i.e. chromosomal instability (CIN) and neuroendocrine (NE) was reported in this outcome measure. rPFS was defined as: time (in months) from randomization to the first occurrence of any one of following: radiological tumor progressions (RECIST1.1), progression of bone lesions (PCWG2 criteria) or death due to any cause. Progression (RECIST1.1): at least a 20% increase in sum of diameters of target lesions, unequivocal progression of existing non-target lesions. Progression of bone lesions (PCWG2 criteria): first bone scan with \>= 2 new lesions compared to Baseline observed \<12 weeks from randomization and confirmed by a second bone scan performed \>=6 weeks later; first bone scan with \>=2 new lesions compared to Baseline observed \>=12 weeks from randomization and new lesions were verified on next bone scan \>= 6 weeks later.

Time frame:
From randomization until tumor progression or bone lesion progression, death due to any cause, or data cut-off date whichever comes first (maximum duration: up to 141 weeks)
Reported as:
Median · months
Radiographic Progression-Free Survival (rPFS) in Participants With Presence and Absence of Biomarker
monthsCabazitaxelAbiraterone Acetate or Enzalutamide
Presence of CIN4.2 (2.1 to 11.2)4.2 (0.03 to 21.0)
Absence of CIN8.5 (0.03 to 33.1)3.4 (0.03 to 28.0)
Presence of NE3.0 (2.6 to 11.2)3.9 (0.03 to 21.0)
Absence of NE8.2 (0.03 to 33.1)3.5 (0.03 to 28.0)

Adverse events

Collected over Adverse event (AE) data was collected from Baseline up to 30 days after the last treatment administration (up to 197 weeks), deaths were collected from baseline up to end of study (up to 197 weeks).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cabazitaxel96/129 (74.4%)49/126 (38.9%)114/126 (90.5%)
Enzalutamide or Abiraterone103/126 (81.7%)50/124 (40.3%)104/124 (83.9%)
Most frequent serious events
Showing 10 of 93
Most frequent serious events
EventCabazitaxelEnzalutamide or Abiraterone
Disease ProgressionGeneral disorders4/1268/124
Back PainMusculoskeletal and connective tissue disorders0/1264/124
Acute Kidney InjuryRenal and urinary disorders3/1264/124
Febrile NeutropeniaBlood and lymphatic system disorders4/1260/124
PneumoniaInfections and infestations4/1261/124
Spinal Cord CompressionNervous system disorders4/1263/124
NauseaGastrointestinal disorders0/1263/124
Urinary Tract InfectionInfections and infestations2/1263/124
HaematuriaRenal and urinary disorders1/1263/124
Renal FailureRenal and urinary disorders0/1263/124
Most frequent other events
Showing 10 of 30
Most frequent other events
EventCabazitaxelEnzalutamide or Abiraterone
DiarrhoeaGastrointestinal disorders50/1268/124
AnaemiaBlood and lymphatic system disorders38/12614/124
FatigueGeneral disorders36/12621/124
AstheniaGeneral disorders33/12626/124
NauseaGastrointestinal disorders29/12626/124
NeutropeniaBlood and lymphatic system disorders28/1261/124
Back PainMusculoskeletal and connective tissue disorders20/12627/124
ArthralgiaMusculoskeletal and connective tissue disorders10/12620/124
Decreased AppetiteMetabolism and nutrition disorders16/12619/124
ConstipationGastrointestinal disorders19/12613/124

Baseline characteristics

Analysis was performed on Intent-to-treat (ITT) population, that included any participant who had been allocated to a randomized treatment regardless of whether the treatment kit was used, analyzed according to the treatment group allocated by randomization.

Age, Continuous
Age, Continuous(years)CabazitaxelAbiraterone Acetate or EnzalutamideTotal
Mean69.7 ± 8.369.7 ± 7.969.7 ± 8.1
Sex: Female, Male
Sex: Female, Male(Participants)CabazitaxelAbiraterone Acetate or EnzalutamideTotal
Female000
Male129126255
Race and Ethnicity Not Collected
Race and Ethnicity Not Collected(Participants)CabazitaxelAbiraterone Acetate or EnzalutamideTotal
Count of participants——0
08

Study locations

65 sites
  • Investigational Site Number 040002
    Linz, 4010, Austria
  • Investigational Site Number 040003
    Wien, 1090, Austria
  • Investigational Site Number 040004
    Wien, 1090, Austria
  • Investigational Site Number 056013
    Brugge, 8310, Belgium
  • Investigational Site Number 056007
    Brussels, 1070, Belgium
  • Investigational Site Number 056003
    Bruxelles, 1000, Belgium
  • Investigational Site Number 056006
    Charleroi, BE-6000, Belgium
  • Investigational Site Number 056001
    Gent, 9000, Belgium
  • Investigational Site Number 056005
    Leuven, 3000, Belgium
  • Investigational Site Number 203005
    Brno, 65653, Czechia
  • Investigational Site Number 203001
    Olomouc, 77900, Czechia
  • Investigational Site Number 203002
    Plzen, 30460, Czechia
  • Investigational Site Number 203003
    Praha 4, 14059, Czechia
  • Investigational Site Number 250010
    Clermont Ferrand, 63011, France
  • Investigational Site Number 250006
    Lyon Cedex 8, 69373, France
  • Investigational Site Number 250004
    Marseille, 13273, France
  • Investigational Site Number 250011
    Montpellier, 34298, France
  • Investigational Site Number 250002
    Paris Cedex 15, 75015, France
  • Investigational Site Number 250013
    Paris, 75005, France
  • Investigational Site Number 250007
    Paris, 75010, France
  • Investigational Site Number 250014
    Plerin, 22190, France
  • Investigational Site Number 250016
    Reims, France
  • Investigational Site Number 250018
    Saint-Mandé, 94160, France
  • Investigational Site Number 250009
    Strasbourg, 67091, France
  • Investigational Site Number 250005
    Suresnes, 92150, France
  • Investigational Site Number 250008
    Tours, 37044, France
  • Investigational Site Number 250001
    Villejuif, 94800, France
  • Investigational Site Number 276028
    Aschaffenburg, 63739, Germany
  • Investigational Site Number 276008
    Berlin, 14179, Germany
  • Investigational Site Number 276022
    Duisburg, 47179, Germany
  • Investigational Site Number 276023
    Essen, 45136, Germany
  • Investigational Site Number 276002
    Frankfurt Am Main, 60488, Germany
  • Investigational Site Number 276007
    Göttingen, 37075, Germany
  • Investigational Site Number 276026
    Jena, 07747, Germany
  • Investigational Site Number 276025
    Lübeck, 23538, Germany
  • Investigational Site Number 276004
    Magdeburg, 39120, Germany
  • Investigational Site Number 276018
    Mannheim, 68167, Germany
  • Investigational Site Number 276006
    Münster, 48149, Germany
  • Investigational Site Number 276003
    Nürtingen, 72622, Germany
  • Investigational Site Number 276010
    Rostock, 18107, Germany
  • Investigational Site Number 276011
    Tübingen, 72076, Germany
  • Investigational Site Number 300001
    Athens, 11528, Greece
  • Investigational Site Number 300005
    Marousi, Athens, 15125, Greece
  • Investigational Site Number 300004
    Thessaloniki, 56429, Greece
  • Investigational Site Number 352001
    Reykjavik, 101, Iceland
  • Investigational Site Number 372001
    Dublin 24, Ireland
  • Investigational Site Number 372003
    Dublin 7, Ireland
  • Investigational Site Number 380004
    Brescia, 25123, Italy
  • Investigational Site Number 380005
    Candiolo, Italy
  • Investigational Site Number 380009
    Meldola, Italy
  • Investigational Site Number 380006
    Napoli, Italy
  • Investigational Site Number 380002
    Pisa, Italy
  • Investigational Site Number 380001
    Roma, 00152, Italy
  • Investigational Site Number 380008
    Verona, Italy
  • Investigational Site Number 528002
    Breda, 4818CK, Netherlands
  • Investigational Site Number 528003
    Nijmegen, 6525GA, Netherlands
  • Investigational Site Number 528005
    Rotterdam, 3015GD, Netherlands
  • Investigational Site Number 528004
    Sittard-Geleen, 6162BG, Netherlands
  • Investigational Site Number 578001
    Grålum, 1714, Norway
  • Investigational Site Number 578002
    Trondheim, 7006, Norway
  • Investigational Site Number 724001
    Barcelona, 08035, Spain
  • Investigational Site Number 724004
    Madrid, 28041, Spain
  • Investigational Site Number 724002
    Madrid, 28046, Spain
  • Investigational Site Number 724003
    Sevilla, 41013, Spain
  • Investigational Site Number 826001
    Sutton, SM25PT, United Kingdom
09

References and documents

Publications

  • de Wit R, Wulfing C, Castellano D, Kramer G, Eymard JC, Sternberg CN, Fizazi K, Tombal B, Bamias A, Carles J, Iacovelli R, Melichar B, Sverrisdottir A, Theodore C, Feyerabend S, Helissey C, Foster MC, Ozatilgan A, Geffriaud-Ricouard C, de Bono J. Baseline neutrophil-to-lymphocyte ratio as a predictive and prognostic biomarker in patients with metastatic castration-resistant prostate cancer treated with cabazitaxel versus abiraterone or enzalutamide in the CARD study. ESMO Open. 2021 Oct;6(5):100241. doi: 10.1016/j.esmoop.2021.100241. Epub 2021 Aug 24. PubMed 34450475 ↗
  • Sternberg CN, Castellano D, de Bono J, Fizazi K, Tombal B, Wulfing C, Kramer G, Eymard JC, Bamias A, Carles J, Iacovelli R, Melichar B, Sverrisdottir A, Theodore C, Feyerabend S, Helissey C, Poole EM, Ozatilgan A, Geffriaud-Ricouard C, de Wit R. Efficacy and Safety of Cabazitaxel Versus Abiraterone or Enzalutamide in Older Patients with Metastatic Castration-resistant Prostate Cancer in the CARD Study. Eur Urol. 2021 Oct;80(4):497-506. doi: 10.1016/j.eururo.2021.06.021. Epub 2021 Jul 15. PubMed 34274136 ↗
  • Fizazi K, Kramer G, Eymard JC, Sternberg CN, de Bono J, Castellano D, Tombal B, Wulfing C, Liontos M, Carles J, Iacovelli R, Melichar B, Sverrisdottir A, Theodore C, Feyerabend S, Helissey C, Oudard S, Facchini G, Poole EM, Ozatilgan A, Geffriaud-Ricouard C, Bensfia S, de Wit R. Quality of life in patients with metastatic prostate cancer following treatment with cabazitaxel versus abiraterone or enzalutamide (CARD): an analysis of a randomised, multicentre, open-label, phase 4 study. Lancet Oncol. 2020 Nov;21(11):1513-1525. doi: 10.1016/S1470-2045(20)30449-6. Epub 2020 Sep 11. PubMed 32926841 ↗
  • de Wit R, de Bono J, Sternberg CN, Fizazi K, Tombal B, Wulfing C, Kramer G, Eymard JC, Bamias A, Carles J, Iacovelli R, Melichar B, Sverrisdottir A, Theodore C, Feyerabend S, Helissey C, Ozatilgan A, Geffriaud-Ricouard C, Castellano D; CARD Investigators. Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer. N Engl J Med. 2019 Dec 26;381(26):2506-2518. doi: 10.1056/NEJMoa1911206. Epub 2019 Sep 30. PubMed 31566937 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2015 to primary completion in Mar 2019, 40 months.

Results were first posted in Feb 2022, 2 years 10 months after primary completion.

Of 52 phase 4 interventional studies under Prostatic Neoplasms, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 67. This study's 40 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 26, 2015
First posted
Jun 30, 2015
StartActual
Nov 9, 2015
Primary completionActual
Mar 27, 2019
CompletionActual
Mar 15, 2021
Results first posted
Feb 14, 2022
Last update
May 27, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 27, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02485691
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Jun 30, 2015
Start date
Nov 9, 2015
Primary completion
Mar 27, 2019
Completion
Mar 15, 2021
Results posted
Feb 14, 2022
Last update
May 27, 2022

Study contacts

Clinical Sciences & Operations
study director · Sanofi

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Cabazitaxel · Enzalutamide · Abiraterone Acetate

Start the discussion